

Prostate cancer: diagnosis and management (update)

NICE guideline: acknowledgments

NICE guideline <number>

Authors and contributors

December 2018

Draft for Consultation

*Commissioned by the National Institute for
Health and Care Excellence*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2018]. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Guideline developers	5
1.1	Members of the NICE guideline committee.....	5
1.2	Members of the Guideline Updates Team:	5
1.3	Acknowledgements	5

1 Guideline developers

1.1 Members of the NICE guideline committee:

Name	Role
Waqar Shah	General Practitioner, London (Guideline Chair)
Abi Ademoyero	Commissioning and Contract Lead, London
Pauline Bagnall	Uro-oncology nurse specialist, Northumbria
Gayan Chetiyawardana	Urology Consultant Radiographer, Rickmansworth, Herts
Charles Frost	Lay member
John Graham	Consultant Clinical Oncologist, Taunton
Sadaf Haque	General Practitioner, Gloucester
Peter Jenkins	Consultant Clinical Oncologist, Cheltenham
Howard Kynaston	Professor of Urological Surgery and Consultant Urological Surgeon, Cardiff
Sanjeev Madaan	Consultant Urological Surgeon, Dartford
Brian McGlynn	Nurse Consultant Urology Oncology, Ayr
Jon Oxley	Consultant Histopathologist, Bristol
Jonathan Richenberg	Consultant Radiologist, Brighton
Mark Robinson	Consultant Radiologist, Newport
Karen Stalbow	Lay member
Rhiannon Walters-Davies	Principal Pharmacist, Cardiff (co-opted expert member)

1.2 Members of the Guideline Updates Team:

Name	Role
Jean Bennie	Technical Analyst
Chris Carmona	Senior Technical Analyst
Fadi Chehadah	Health Economist (From January 2018)
Clare Dadswell	Technical Analyst (From May 2018 to July 2018)
Jenny Kendrick	Information Specialist
Adam O'Keefe	Project Manager (Until October 2018)
Rebecca Parsons	Project Manager (From October 2018)
Gabriel Rogers	Technical Adviser (Health Economics)
Susan Spiers	Associate Director

1.3 Acknowledgements

The development of this guideline was greatly assisted by the following people:

- The PROMIS investigators, particularly Rita Faria (the Centre for Health Economics, University of York), Louise Brown (MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology), Mark Emberton (Division of Surgery and Interventional Science, University College London) and Hashim Ahmed (Department of Surgery and Cancer, Imperial College London)
- The ProtecT investigators, particularly Freddie Hamdy (the Nuffield Department of Surgical Sciences, University of Oxford) and Jenny Donovan (Department of Social Medicine, University of Bristol)

- The STAMPEDE investigators, particularly Beth Woods (the Centre for Health Economics, University of York), Mark Sculpher (the Centre for Health Economics, University of York) and Matt Sydes (MRC Clinical Trials Unit at UCL)
- The SPCG4 investigators, particularly Anna Bill-Axelsson (Department of Surgical Sciences, Uppsala University)
- Vincent Gnanapragasam from the Academic Urology Group, University of Cambridge.